New Recommendations Pinpoint Who Starts Aduhelm Treatment and When to Stop

By | Drug Industry Daily | No Comments

Patients who want to start treatment with Biogen’s newly approved Alzheimer’s drug, Aduhelm (aducanumab), should undergo cognitive testing, brain imaging to exclude cerebrovascular disease and have either a lumbar puncture or PET scan to confirm the presence of cerebral amyloid, a new set of treatment recommendations advises.
Source: Drug Industry Daily